Neuroleptic malignant syndrome after venlafaxlne (multiple letters)

Lancet

Volumn 355, Issue 9221, 2000, Pages 2164-2165

  Cassidy, E M ^a   O'Kearne, V ^a   Nimmagadda, S R ^a   Ryan, D H ^a   Atkin, S L ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN MONOAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MUSCLE RELAXANT AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRIFLUOPERAZINE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL FEATURE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG OVERDOSE; EXTRAPYRAMIDAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; LETTER; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY DYSFUNCTION; SEROTONIN BRAIN LEVEL; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM;

EID: 0034679287     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)72790-2     Document Type: Letter

References (5)

1. SR Nimmagadda DH Ryan SL Atkin Neuroleptic malignant syndrome after venlafaxine Lancet 354 2000 289 290
2. C Wikell PB Bergqvist S Hjorth G Apelqvist H Bjork F Bengtsoon Brain monoamine output alterations after a single dose of venlafaxine challenge in experimental hepatic encephalopathy Clin Neuropharmcol 21 1998 296 306
3. KC Mills Serotonin syndrome: a clinical update Crit Care Clin 13 1997 763 783
4. A Adityanjee T Mathews YA Aberibigbe Proposed research diagnostic criteria for neuroleptic malignant syndrome Int J Neuropsychopharmacol 2 1999 129 144
5. P Kolecki Isolated venlafaxine-induced serotonin syndrome J Emerg Med 15 1997 491 493